CLADQoL: CLADribine tablets –evaluation of Quality of Life
- Conditions
- G35Multiple sclerosis
- Registration Number
- DRKS00013934
- Lead Sponsor
- Merck Healthcare Germany GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 315
Inclusion Criteria
Patients (male or female) aged 18-55 years
- All patients eligible to receive Cladribine tablets as per registered label
- Patients using Cladribine tablets for the first time
- Signed informed consent
Exclusion Criteria
- Existing pregnancy or lactation
- Contraindications to use of Cladribine tablets according to the Summary of Product Characteristics
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the health related quality of life through the MSQOL-54 scale in relapsing multiple sclerosis patients treated with Cladribine Tablets for 24 months<br>The MSQOL-54 is filled in at the beginning of the study (baseline), after 12, 24, 36 and 48 months.
- Secondary Outcome Measures
Name Time Method